Comparison of Culture- and Non-Culture-Based Methods for Quantification of Viral Load and Resistance to Antiretroviral Drugs in Patients Given Zidovudine Monotherapy
暂无分享,去创建一个
D. Jeffries | C. Loveday | R. Tedder | J. Weber | J. Darbyshire | A. Babiker | R. Foxall | I. Weller | S. Kaye | J. Norman | M. Bourelly
[1] K. Harada,et al. Direct Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of Defects , 1996, Science.
[2] J. Darbyshire,et al. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals , 1996, The Lancet.
[3] John W. Mellors,et al. Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.
[4] C. Loveday,et al. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy , 1995, The Lancet.
[5] D. Ho,et al. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. , 1995, AIDS research and human retroviruses.
[6] D. van Strijp,et al. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. , 1994, Journal of virological methods.
[7] Ann Marie Swart,et al. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection , 1994, The Lancet.
[8] J. Sninsky,et al. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection , 1994, Journal of clinical microbiology.
[9] B. Larder,et al. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates , 1994, Antimicrobial Agents and Chemotherapy.
[10] J. Currier. Zidovudine for asymptomatic human immunodeficiency virus infection , 1994, ACP Journal Club.
[11] B. Larder,et al. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing , 1993, Nature.
[12] J. Condra,et al. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors , 1993, Antimicrobial Agents and Chemotherapy.
[13] S. Bloor,et al. Variable relationship between proviral DNA load and infectious virus titre in the peripheral blood mononuclear cells of HIV‐1‐infected individuals , 1993, AIDS.
[14] D. Katzenstein,et al. Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. , 1993, Journal of acquired immune deficiency syndromes.
[15] S. J. Clark,et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. , 1993, Science.
[16] C. Loveday,et al. HIV-1 plasma viraemia quantification: a non-culture measurement needed for therapeutic trials. , 1993, Journal of virological methods.
[17] C. Loveday,et al. A microtitre format point mutation assay: Application to the detection of drug resistance in human immunodeficiency virus type‐1 infected patients treated with zidovudine , 1992, Journal of medical virology.
[18] H. Mitsuya,et al. Plasma HIV-1 viremia in HIV-1 infected individuals assessed by polymerase chain reaction. , 1992, AIDS research and human retroviruses.
[19] F. Brun-Vézinet,et al. HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase. , 1992, Journal of virological methods.
[20] B. Larder,et al. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[21] S D Kemp,et al. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. , 1991, AIDS.
[22] S W Lagakos,et al. Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection , 1990 .
[23] P. Simmonds,et al. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers , 1990, Journal of virology.
[24] D. Ho,et al. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1989, The New England journal of medicine.
[25] A. Collier,et al. Plasma viremia in human immunodeficiency virus infection. , 1989, The New England journal of medicine.
[26] S D Kemp,et al. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). , 1989, Science.
[27] Andreas Meyerhans,et al. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations , 1989, Cell.
[28] D. Katzenstein,et al. Plasma viremia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment. , 1992, Journal of acquired immune deficiency syndromes.
[29] B. Larder,et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. , 1992, The Journal of infectious diseases.
[30] M. Ascher,et al. A multicenter proficiency trial of gene amplification (PCR) for the detection of HIV-1. , 1991, Journal of acquired immune deficiency syndromes.
[31] R. Higuchi,et al. Simple and Rapid Preparation of Samples for PCR , 1989 .